Taxotere (docetaxel), a popular chemotherapy drug manufactured by Sanofi-Aventis, has been linked to permanent hair loss, or alopecia, in some women. While hair loss is a common side effect for patients undergoing chemotherapy treatment, this drug has been known to prevent future growth of hair. The manufacturer failed to warn women of this risk.
Taxotere is often given to women who have been diagnosed with breast cancer and must undergo chemotherapy as part of their treatment. Taxotere requires patients to take the drug once every three weeks, as opposed to a weekly treatment like other common chemotherapy drugs. This can be of great convenience to patients who do not have the time to come in for treatment on a weekly basis.
Alopecia is a common, but distressing, side effect of chemotherapy. However, permanent and irreversible hair loss is not intended. Unfortunately, studies have shown that women who were treated for breast cancer with Taxotere presented with moderate or intense alopecia, which ended up permanent and severe in their cases. This unimagined side effect severely decreases a patient’s quality of life, and can negatively affect an individual’s body image causing depression and pain.
Each year, almost 250,000 women are diagnosed with breast cancer, and they may be treated with Taxotere. Breast cancer survivors who were treated with Taxotere are now filing lawsuits against the manufacturer, claiming that the company failed to warn them of the risk of permanent side effects associated with the drug, such as alopecia.
If you or a loved one has suffered permanent hair loss after taking Taxotere, please contact us today for a free and confidential case evaluation. At McDivitt Law Firm, we continue our commitment to putting our clients first, and, as always, we welcome the opportunity to help you.